COVID-19疫苗接种后发生心脏不良事件个体的再接种:加拿大免疫研究网络研究
该研究分析了加拿大免疫研究网络十二个站点中因COVID-19疫苗接种后疑似心脏不良事件转诊的114名参与者,按布莱顿协作病例定义分类,随访再接种后42天内不良事件复发情况。再接种的16人中4人出现症状复发,作者认为不符合心肌炎标准的胸痛个体可考虑再接种,但对先前确诊心肌心包炎的成人需谨慎。
要点
- 114名参与者中46例(40.4%)为心肌炎,26例(22.8%)为心肌心包炎,11例(9.6%)为心包炎,31例(27.1%)为胸痛/其他心脏诊断。
- 需再接种的71人中27人(38.0%)被建议再接种,实际再接种16人,4人出现不良事件症状复发。
- 作者认为不符合心肌炎标准的胸痛个体可考虑再接种,但对先前确诊心肌心包炎的成人需谨慎。
核心结论
- 作者认为,对于不符合心肌炎标准的胸痛个体,可考虑进行COVID-19 mRNA疫苗再接种,但对COVID-19 mRNA疫苗接种后确诊心肌心包炎的成人需谨慎。
研究设计与样本
- 研究分析了特殊免疫接种门诊网络数据库,包含十二个站点中知情同意参与者的数据,再接种建议基于医生判断并参考国家指南,随访至再接种后42天以捕捉不良事件复发。
主要发现
- 2021年1月1日至2023年2月23日共纳入114名参与者,中心肌炎46例(40.4%)、心肌心包炎26例(22.8%)、心包炎11例(9.6%)、胸痛/其他心脏诊断31例(27.1%)。
- 需要进一步接种COVID-19疫苗的71名参与者中,27名(38.0%)被建议再接种。
- 16名参与者再接种,包括心肌炎2例、心肌心包炎2例、心包炎2例、胸痛/其他心脏诊断10例。
- 4名成人出现不良事件症状复发:先前胸痛/其他心脏诊断者2/10,先前心包炎且有多种合并症者1例,先前心肌心包炎且需住院者1例。
临床怎么用
- 作者认为,对于不符合心肌炎标准的胸痛个体,可考虑COVID-19 mRNA疫苗再接种。
- 作者认为,对COVID-19 mRNA疫苗接种后确诊心肌心包炎的成人再接种需谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Myocarditis and pericarditis are well-described rare adverse events following immunization (AEFI) associated with COVID-19 mRNA vaccines. Safety data on revaccination among people with previous cardiac AEFIs are lacking. This study assessed outcomes of COVID-19 revaccination among participants assessed for cardiac AEFIs. METHODS: The Special Immunization Clinic Network database, containing data from consented participants across twelve sites, was analyzed. Cases were classified using the Brighton Collaboration Case Definitions (BCCDs) for mutually exclusive diagnoses of myocarditis, myopericarditis or pericarditis. Subjects with cardiac symptoms not meeting the BCCD and with no alternative diagnosis were categorized as chest pain/other cardiac diagnosis. Revaccination recommendations were based on physician judgment, informed by national guidelines. Participants were followed up to 42 days after revaccination to capture AEFI recurrence. RESULTS: Between January 1, 2021 and February 23, 2023, 114 participants were enrolled, including 46 with myocarditis (40.4 %), 26 (22.8 %) with myopericarditis, 11 (9.6 %) with pericarditis, and 31 (27.1 %) with chest pain/other cardiac diagnosis. Twenty-seven of 71 participants (38.0 %) who required further COVID-19 vaccine doses were recommended for revaccination. Sixteen participants were revaccinated: two with myocarditis, two with myopericarditis, two with pericarditis and 10 with chest pain/other cardiac diagnosis. Four adults had recurrent symptoms of the AEFI: 2/10 with previous chest pain/other cardiac diagnosis, one participant with previous pericarditis and multiple comorbid conditions, and one participant with previous myopericarditis who required hospitalization. CONCLUSIONS: COVID-19 mRNA revaccination may be considered for individuals with chest pain not meeting criteria for myocarditis but caution is warranted in adults with prior confirmed myopericarditis post-COVID-19 mRNA vaccination.
引用
- Piché-Renaud PP, Buchan CA, Burton C, et al. Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study. Vaccine. 2025. PMID: 41317434. doi:10.1016/j.vaccine.2025.128016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。